Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disease-modifying drugs for multiple sclerosis: current and future aspects.

Mark S Freedman1

  • 1University of Ottawa and Ottawa Health Research Institute, Canada. mfreedman@ottawahospital.on.ca.

Expert Opinion on Pharmacotherapy
|October 6, 2006
PubMed
Summary

Multiple sclerosis (MS) is a common CNS disorder. Disease-modifying therapies, including interferons and glatiramer acetate, have emerged, offering hope for altered disease course and future treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Multiple sclerosis and related disorders·2026
Same author

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026
Same author

Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian society of clinical chemists (CSCC).

Clinical biochemistry·2026
Same author

Demographic and Clinical Characteristics of Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder in Canadian Adults.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same author

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Neurology·2025

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) is the most prevalent inflammatory demyelinating disease of the central nervous system (CNS).
  • Affecting approximately 2.5 million individuals globally, MS significantly impacts patient health and healthcare systems.
  • Historically, MS treatment focused on symptom management, with limited options to alter disease progression.

Purpose of the Study:

  • To review the current landscape of disease-modifying therapies for multiple sclerosis.
  • To highlight the impact of newly introduced treatments on the natural course of MS.
  • To discuss the future directions and potential of ongoing MS research.

Main Methods:

  • Review of existing literature on multiple sclerosis treatments.
  • Analysis of the efficacy and application of current disease-modifying therapies.

Related Experiment Videos

  • Exploration of emerging research avenues in MS therapeutics.

    • Main Results:

    • The introduction of disease-modifying therapies has revolutionized MS management since the 1990s.
    • Current treatments include interferons (IFN-beta1a, IFN-beta1b) and glatiramer acetate.
    • These therapies aim to modify the disease's natural progression, offering improved outcomes.

    Conclusions:

    • Disease-modifying therapies represent a significant advancement in managing multiple sclerosis.
    • Ongoing research holds promise for developing novel and more effective treatments for MS.
    • The future of MS treatment is optimistic, with continuous exploration of therapeutic targets.